Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on EquityReturn on SalesTimes Interest Earned

Exousia Bio (LMMY) EBITDA Margin (2023 - 2024)

Lamy (LMMY) has disclosed EBITDA Margin for 2 consecutive years, with 17.76% as the latest value for Q3 2024.

  • Quarterly EBITDA Margin changed N/A to 17.76% in Q3 2024 from the year-ago period, while the trailing twelve-month figure was 113.81% through May 2025, up 5926.0% year-over-year, with the annual reading at 465.73% for FY2025, 31386.0% down from the prior year.
  • EBITDA Margin hit 17.76% in Q3 2024 for Lamy, down from 289.04% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 289.04% in Q2 2024 to a low of 224.39% in Q1 2024.